ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

Herberman Leaving NCI To Head New Pittsburgh Institute

July 12, 1985

House Subcommittee Recommends $137.7 Million Increase For NCI

June 21, 1996

Vanderbilt-Ingram Cancer Center Wins NCI’s Comprehensive Designation.

March 16, 2001

Alimta Granted Approval As NSCLC Continuation Therapy

November 25, 2011

DCPC Advisors Okay Minority Based CCOPs, RFA In Native Americans

January 15, 1993

Adriamycin Update Discussed At Seminar

January 10, 1975